



Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Marina Lopez-Martinez^{1,2}, Irina Torres^{1,2}, Sheila Bermejo^{1,2}, Francesc Moreso^{1,2*}, Clara Garcia-Carro^{3,4}, Ander Vergara^{1,2}, Natalia Ramos^{1,2}, Manel Perello^{1,2}, Alejandra Gabaldon^{2,5}, M. Antonieta Azancot^{1,2}, Monica Bolufer^{1,2}, Nestor Toapanta^{1,2}, Oriol Bestard^{1,2}, Irene Agraz-Pamplona^{1,2†} and Maria Jose Soler^{1,2*†}

¹Department of Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain, ²Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Vall d'Hebron University Hospital, Barcelona, Spain, ³Department of Nephrology, San Carlos Clinical University Hospital, Madrid, Spain, ⁴Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), San Carlos Clinical University Hospital, Madrid, Spain, ⁵Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain

OPEN ACCESS

*Correspondence:

Francesc Moreso
fjmoreso@vhebron.net
Maria Jose Soler
mjsoler01@gmail.com

†These authors share senior authorship

Received: 22 November 2022

Accepted: 07 December 2022

Published: 05 January 2023

Keywords: IgA nephropathy, IgAN recurrence in transplant kidney, proteinuria reduction, TRF-budesonide, CKD progression

A Corrigendum on

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice by Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2022). *Transpl Int.* 35:10693. doi: 10.3389/ti.2022.10693

In the original article, there was a mistake in **Table 1** as published. Since publication, it has been noticed that the rows “BMI (Kg/m²)” and “LDL (mg/dl)” incorrectly contained repeated data. The corrected version of **Table 1** is shown below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2023 Lopez-Martinez, Torres, Bermejo, Moreso, Garcia-Carro, Vergara, Ramos, Perello, Gabaldon, Azancot, Bolufer, Toapanta, Bestard, Agraz-Pamplona and Soler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Citation:
Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2023) Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. *Transpl Int* 35:11073. doi: 10.3389/ti.2022.11073

TABLE 1 | Change from baseline of analytical parameters.

	Baseline	3 months	6 months	12 months	24 months
UPCR native-kidney (Relative decrease %)	1.2 (0.70–2.80)	0.81 (0.8–0.93) –32.5	0.53 (0.18–0.85) –55.8	1.10 (0.16–1.35) –8.3	0.74 (0.30–1.70) –38.3
UPCR transplant-kidney (Relative decrease %)	1.5 (0.78–4.3)	1.1 (0.39–1.55)* –26.7	0.59 (0.17–1.40) –60.7	0.75 (0.16–1.33) –50.0	1.27 (0.55–1.70) –15.3
UPCR total (Relative decrease %)	1.3 (0.72–4.23)	0.87 (0.54–1.18)* –33.1	0.59 (0.17–0.85)* –54.6	1.10 (0.21–1.30) –15.4	0.92 (0.36–1.83) –29.2
Creatinine (mg/dl)	1.66 ± 0.83	1.89 ± 1.62	1.41 ± 0.53	1.37 ± 0.60	1.78 ± 0.49
CKD-EPI (ml/min)	57.14 ± 24.49	57.07 ± 27.71	62.33 ± 23.00	65.63 ± 25.39	57.40 ± 25.47
Haematuria (yes %)	9 (69.2)	8 (61.5)	5 (50)	6 (75)	5 (100)
BMI (kg/m ²)	27.19 ± 6.70	26.25 ± 6.49	28.95 ± 7.68	23.93 ± 2.06	23.3 ± 2.48
LDL (mg/dl)	112.73 ± 50.53	99.18 ± 31.74	91.63 ± 25.89	101.67 ± 39.64	108.40 ± 38.06
HbA1c (%)	5.89 ± 0.98	5.40 ± 0.30	6.07 ± 1.57	5.53 ± 0.85	5.22 ± 0.40
Clinical adverse events (yes %)	0	0	0	0	0

Median values (interquartile range 25/75 within parentheses) and relative decrease percentage of urine protein to creatinine ratio (UPCR), mean values (SD) of creatinine and estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI), presence of haematuria, body mass index (BMI), low density lipoprotein (LDL), HbA1c, and clinical adverse events before and after 3-, 6-, 12-, and 24-month treatment with budesonide was started. *p < 0.05 versus baseline.